AR114392A1 - Tratamiento de pacientes con enfermedad de fabry clásica - Google Patents

Tratamiento de pacientes con enfermedad de fabry clásica

Info

Publication number
AR114392A1
AR114392A1 ARP190100287A ARP190100287A AR114392A1 AR 114392 A1 AR114392 A1 AR 114392A1 AR P190100287 A ARP190100287 A AR P190100287A AR P190100287 A ARP190100287 A AR P190100287A AR 114392 A1 AR114392 A1 AR 114392A1
Authority
AR
Argentina
Prior art keywords
patient
renal
fabry disease
reduce
patients
Prior art date
Application number
ARP190100287A
Other languages
English (en)
Spanish (es)
Inventor
Elfrida Benjamin
Jay Barth
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR114392(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AR114392A1 publication Critical patent/AR114392A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP190100287A 2018-02-06 2019-02-06 Tratamiento de pacientes con enfermedad de fabry clásica AR114392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06

Publications (1)

Publication Number Publication Date
AR114392A1 true AR114392A1 (es) 2020-09-02

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100287A AR114392A1 (es) 2018-02-06 2019-02-06 Tratamiento de pacientes con enfermedad de fabry clásica

Country Status (20)

Country Link
US (1) US20210038579A1 (enExample)
EP (2) EP4316589A3 (enExample)
JP (2) JP2021512896A (enExample)
KR (1) KR20200128675A (enExample)
CN (1) CN112203657A (enExample)
AR (1) AR114392A1 (enExample)
AU (2) AU2019217603A1 (enExample)
DK (1) DK3749308T3 (enExample)
ES (1) ES2969263T3 (enExample)
FI (1) FI3749308T3 (enExample)
HR (1) HRP20240025T1 (enExample)
HU (1) HUE064761T2 (enExample)
LT (1) LT3749308T (enExample)
PL (1) PL3749308T3 (enExample)
PT (1) PT3749308T (enExample)
RS (1) RS65103B1 (enExample)
SI (1) SI3749308T1 (enExample)
SM (1) SMT202400027T1 (enExample)
TW (1) TWI869336B (enExample)
WO (1) WO2019157056A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
JP2024525760A (ja) * 2021-07-12 2024-07-12 アミカス セラピューティックス インコーポレイテッド 小児患者のファブリー病を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) * 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
EA202090242A1 (ru) * 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

Also Published As

Publication number Publication date
EP3749308A1 (en) 2020-12-16
SI3749308T1 (sl) 2024-03-29
HRP20240025T1 (hr) 2024-03-29
FI3749308T3 (fi) 2024-01-18
AU2025200074A1 (en) 2025-01-30
WO2019157056A8 (en) 2020-12-03
PT3749308T (pt) 2024-01-25
EP4316589A3 (en) 2024-04-24
KR20200128675A (ko) 2020-11-16
DK3749308T3 (da) 2024-01-22
US20210038579A1 (en) 2021-02-11
EP3749308B1 (en) 2023-10-25
TW201944998A (zh) 2019-12-01
AU2019217603A1 (en) 2020-09-24
SMT202400027T1 (it) 2024-03-13
CN112203657A (zh) 2021-01-08
CA3090499A1 (en) 2019-08-15
ES2969263T3 (es) 2024-05-17
TWI869336B (zh) 2025-01-11
PL3749308T3 (pl) 2024-03-25
EP4316589A2 (en) 2024-02-07
JP2024026080A (ja) 2024-02-28
TW202537622A (zh) 2025-10-01
RS65103B1 (sr) 2024-02-29
HUE064761T2 (hu) 2024-04-28
LT3749308T (lt) 2024-02-12
WO2019157056A1 (en) 2019-08-15
JP2021512896A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
AR134835A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
CL2021003280A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
PH12020500555A1 (en) Esketamine for the treatment of depression
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
WO2019157056A8 (en) Treatment of patients with classic fabry disease
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202190569A1 (ru) Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2024004514A (es) Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
EP4324522A3 (en) Methods of treating fabry patients having renal impairment
AR111971A1 (es) Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
AR109102A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
EA201992869A1 (ru) Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность
BR112013017829A2 (pt) método de tratamento de um paciente com sintomas de prostatite e/ou síndrome da dor pélvica e método de tratamento de um paciente com sintomas de prostatite crônicas/síndrome de dor pélvica crônica